Telix Launches Groundbreaking ZOLAR Trial for Soft Tissue Sarcoma

Telix Pharmaceuticals has announced a major milestone in cancer research, dosing the first patient in its Phase 1 ZOLAR trial at the Melbourne Theranostic Innovation Centre (MTIC) in Australia. The study is evaluating TLX300-CDx (89Zr-olaratumab), a novel PET imaging agent targeting platelet-derived growth factor receptor alpha (PDGFRα)—a protein commonly overexpressed in soft tissue sarcoma (STS). As a first-in-human, proof-of-concept trial, ZOLAR aims to assess safety, biodistribution, and pharmacokinetics, setting the stage for future therapeutic applications. Given the poor response of metastatic STS to chemotherapy, Telix’s theranostic approach offers a promising alternative to traditional treatments.

“Sarcomas are rare and often resistant to chemotherapy, making targeted therapies like TLX300-CDx a crucial advancement,” said Professor Rodney Hicks, Principal Investigator at MTIC. By leveraging precision diagnostics and radionuclide therapy, Telix aims to transform treatment for STS patients worldwide. Dr. David N. Cade, Telix’s Chief Medical Officer, expressed gratitude to the MTIC team and trial participants, emphasizing the trial’s potential to shape the future of personalized cancer care. With this trial, Telix moves closer to a novel, targeted therapy that could revolutionize the management of advanced STS.